Amgen (AMGN) Stock Price, News & Analysis

+1.80 (+0.66%)
(As of 12:15 PM ET)
Today's Range
50-Day Range
52-Week Range
638,343 shs
Average Volume
2.82 million shs
Market Capitalization
$146.81 billion
P/E Ratio
Dividend Yield
Price Target

Amgen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.53 Rating Score
8.6% Upside
$296.95 Price Target
Short Interest
1.96% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.23mentions of Amgen in the last 14 days
Based on 34 Articles This Week
Insider Trading
Proj. Earnings Growth
From $19.45 to $20.96 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.77 out of 5 stars

Medical Sector

48th out of 910 stocks

Biological Products, Except Diagnostic Industry

5th out of 153 stocks

AMGN stock logo

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Stock Price History

AMGN Stock News Headlines

Biotech Sector Nears Breakout: Will it Outperform in Q2?
The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.
Biotech Sector Nears Breakout: Will it Outperform in Q2? (AMGN)
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
7 Stocks That Will Drive the Weight Loss Drugs Market (AMGN)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Amgen (NASDAQ:AMGN) PT Lowered to $284.00
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Amgen (NASDAQ:AMGN) Given New $360.00 Price Target at TD Cowen
Short Interest in Amgen Inc. (NASDAQ:AMGN) Declines By 5.8%
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Amgen: I Prefer To Chase Value And Dividends
Amgen: The Giant With An Impressive Pipeline
Amgen (NASDAQ:AMGN) Rating Reiterated by Truist Financial
Is Amgen Stock a Buy?
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 3/7 Dividend
Dividend Payable
Next Earnings (Confirmed)
Ex-Dividend for 6/7 Dividend
Dividend Payable
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
19 Analysts


Net Income
$6.72 billion
Pretax Margin


Sales & Book Value

Annual Sales
$28.19 billion
Cash Flow
$26.66 per share
Book Value
$11.65 per share


Free Float
Market Cap
$145.85 billion

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Should I Buy Amgen Stock? AMGN Pros and Cons Explained


Here are some ways that investors could benefit from investing in Amgen Inc.:

  • Amgen Inc. has a diverse portfolio of products, including Enbrel, Otezla, and Repatha, which have shown strong performance in treating various medical conditions.
  • Recent earnings report showed a positive trend with earnings per share exceeding analyst estimates, indicating strong financial performance.
  • Amgen Inc. announced a quarterly dividend, providing investors with a steady income stream and a yield of 3.28%.
  • The company has a strong return on equity of 154.27%, reflecting efficient use of shareholder equity to generate profits.
  • Despite a recent stock price decline, Amgen Inc. has a solid market capitalization of $147.07 billion, indicating stability and long-term growth potential.


Investors should be bearish about investing in Amgen Inc. for these reasons:

  • Amgen Inc. has a relatively high debt-to-equity ratio of 10.14, which may pose risks in terms of financial leverage and debt repayment.
  • The stock price has experienced fluctuations, with a 52-week low of $211.71, indicating potential volatility in the market.
  • Amgen Inc.'s P/E ratio of 22.11 and P/E/G ratio of 2.67 may suggest that the stock is currently overvalued compared to its growth prospects.
  • Investors should consider the competitive landscape in the biotechnology industry, as Amgen Inc. faces competition from other major players in the market.
  • While the company has a strong product pipeline, regulatory challenges and patent expirations could impact future revenue streams and profitability.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Amgen pros and cons to

AMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMGN shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price target for 2024?

19 Wall Street research analysts have issued 1 year price targets for Amgen's stock. Their AMGN share price targets range from $200.00 to $360.00. On average, they predict the company's share price to reach $296.95 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2024?

Amgen's stock was trading at $288.02 at the start of the year. Since then, AMGN stock has decreased by 5.1% and is now trading at $273.43.
View the best growth stocks for 2024 here

Are investors shorting Amgen?

Amgen saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 10,470,000 shares, a decrease of 5.8% from the March 15th total of 11,110,000 shares. Based on an average daily trading volume, of 2,920,000 shares, the short-interest ratio is presently 3.6 days. Approximately 2.0% of the shares of the stock are short sold.
View Amgen's Short Interest

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AMGN earnings forecast

How can I listen to Amgen's earnings call?

Amgen will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 647-362-9199 with passcode "8744136".

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Tuesday, February, 6th. The medical research company reported $4.71 EPS for the quarter, beating the consensus estimate of $4.66 by $0.05. The medical research company had revenue of $8.20 billion for the quarter, compared to analysts' expectations of $8.13 billion. Amgen had a net margin of 23.83% and a trailing twelve-month return on equity of 154.27%. The firm's revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the company earned $4.09 earnings per share.
Read the conference call transcript

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 6th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share on Friday, June 7th. This represents a $9.00 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date is Thursday, May 16th.
Read our dividend analysis for AMGN

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 3.35%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 72.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.94% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 18.900-20.300 for the period, compared to the consensus EPS estimate of 20.000. The company issued revenue guidance of $32.4 billion-$33.8 billion, compared to the consensus revenue estimate of $32.7 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.31%), Sarasin & Partners LLP (0.21%), Raymond James & Associates (0.20%), Raymond James Financial Services Advisors Inc. (0.09%), Wealth Enhancement Advisory Services LLC (0.06%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
This page (NASDAQ:AMGN) was last updated on 4/23/2024 by Staff

From Our Partners